Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation
A use of an anti-inflammatory polysaccharides composition comprising fucans and galactans to inhibit the release of one or more of IL-8, PGE2 and VEGF by a cell activated during an inflammatory process and an anti-inflammatory composition comprising a ratio of brown algae fucans/red algae galactans of between about 2.5/1 (w/w) to about 40/1 (w/w), the galactans having a molecular weight higher than about 100 kDa, and the fucans having a molecular weight between about 0.1 kDa and 100 kDa.
1. A method for inhibiting the release of one or more of IL-8, PGE2 and VEGF by a cell activated during an inflammatory process, said method comprising administering to said cell an anti-inflammatory polysaccharide composition comprising brown algae fucans and red algae galactans, wherein the fucans and the galactans in said composition are present in a ratio ranging from about 2.5 fucans/1 galactan (w/w) to about 40 fucans/1 galactan (w/w);
said galactans having:
(i) an average molecular weight higher than about 100 kDa;
(ii) a galactose content ranging from about 30 to about 40% of dry weight of the galactans;
(iii) a sulfate content ranging from about 20 to about 35% of dry weight of the galactans; and
(iv) an uronic acid content ranging from about 1 to about 5% of dry weight of the galactans;
and said fucans having:
(v) an average molecular weight ranging from about 5 kDa to about 100 kDa;
(vi) a fucose content ranging from about 20 to about 35% of dry weight of the fucans;
(vii) a sulfate content ranging from about 15 to about 25% of dry weight of the fucans; and
(viii) an uronic acid content ranging from about 10 to about 29% of dry weight of the fucans,
wherein the ratio of fucans to galactans in said composition enables a reduction in the cytotoxicity of said galactans.
2. The method of claim 1 , wherein the release of IL-8, PGE2 and VEGF is from epithelial cells.
3. The method of claim 1 , wherein the fucans increase the inhibition of inflammation.
4. The method of claim 1 , wherein said red algae are Asparagopsis armata.
5. The method of claim 1 , wherein said brown algae are Ascophyllum nodosum.
6. The method of claim 1 , wherein the galactans have an average molecular weight of about 350 kDa.
7. The method of claim 1 , wherein the galactans have a galactose content of about 37% of dry weight of the galactans.
8. The method of claim 1 , wherein the galactans have an uronic acid content of about 3% of dry weight of the galactans.
9. The method of claim 1 , wherein the galactans have a sulfate content of about 27% of dry weight of the galactans.
10. The method of claim 1 , wherein the fucans have an average molecular weight ranging from about 5 kDa to about 25 kDa.
11. The method of claim 1 , wherein the fucans and the galactans are present in a ratio of about 10 fucans/1 galactans (w/w) in the composition.
12. The method of claim 1 , wherein the galactans comprise native galactans.
13. The method of claim 1 , wherein the fucans comprise native fucans.
14. The method of claim 1 , wherein the fucans comprise depolymerized fucans.
15. The method of claim 1 , wherein the fucans comprise demineralized fucans.
16. The method of claim 1 , wherein the galactans comprise demineralized galactans.
17. The method of claim 1 , wherein said composition is administered topically.
18. The method of claim 17 , for alleviating skin disorders or conditions caused by UV exposure, chemical stress, aggression from pollutants, exfoliating agents or skin irritants.
19. The method of claim 17 , for reducing skin disorders or conditions caused by UV exposure, chemical stress, aggression from pollutants, exfoliating agents or skin irritants.
20. An anti-inflammatory composition comprising brown algae fucans and red algae galactans, wherein the ratio of brown algae fucans/red algae galactans in said composition is ranging from about 2.5/1 (w/w) to about 40/1 (w/w), said galactans having:
(i) an average molecular weight higher than about 100 kDa;
(ii) a galactose content ranging from about 30 to about 40% of dry weight of the galactans;
(iii) a sulfate content ranging from about 20 to about 35% of dry weight of the galactans; and
(iv) an uronic acid content ranging from about 1 to about 5% of dry weight of the galactans;
and said fucans having:
(v) an average molecular weight ranging from about 5 kDa to about 100 kDa;
(vi) a fucose content ranging from about 20 to about 35% of dry weight of the fucans;
(vii a sulfate content ranging from about 15 to about 25% of dry weight of the fucans; and
(viii) an uronic acid content ranging from about 10 to about 29% of dry weight of the fucans;
wherein the ratio of fucans to galactans in said composition enables a reduction in the cytotoxicity of said galactans.
21. The composition of claim 20 , wherein the galactans have an average molecular weight of about 350 kDa.
22. The composition of claim 20 , wherein the galactans have a galactose content of about 37% of dry weight of the galactans.
23. The composition of claim 20 , wherein the galactans have an uronic acid content of about 3% of dry weight of the galactans.
24. The composition of claim 20 , wherein the galactans have a sulfate content of about 27% of dry weight of the galactans.
25. The composition of claim 20 , wherein the fucans have an average molecular weight ranging from about 5 kDa to about 25 kDa.
26. The composition of claim 20 , the ratio of brown algae fucans/red algae galactans being of 10/1.
27. The composition of claim 20 , the galactans having a molecular weight of about 350 kDa, and the fucans having a molecular weight ranging from about 15 kDa and about 25 kDa.
28. The composition of claim 20 , wherein the brown algae is Ascophyllum nodosum.
29. The composition of claim 20 , wherein the red algae is Asparagopsis armata.
30. The composition of claim 20 , wherein the galactans comprise native galactans.
31. The composition of claim 20 , wherein the fucans comprise native fucans.
32. The composition of claim 20 , wherein the fucans comprise depolymerized fucans.
33. The composition of claim 20 , wherein the fucans comprise demineralized fucans.
34. The composition of claim 20 , wherein the galactans comprise demineralized galactans.
35. The composition of claim 20 , which is a topical composition.
36. The composition of claim 35 , which is a cosmetic composition.
37. The method of claim 1 , wherein the cell is within a subject.
38. The method of claim 37 , wherein the polysaccharide composition is topically administered to the subject.
39. The method of claim 38 , wherein the subject is a human affected by skin disorders or conditions caused by UV exposure, chemical stress, aggression from pollutants, exfoliating agents or skin irritants.
40. The composition of claim 20 , wherein the fucans have an average molecular weight ranging from about 5 kDa to about 25 kDa.